Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021. The document serves as a transaction notification regarding a specific executive compensation event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It details a single transaction involving a cash payment to an executive:
- Transaction Type: Cash payment in lieu of share vesting under the Deferred Investment Award programme.
- Executive: Mr. R Simard (President, Pharmaceuticals Supply Chain).
- Volume: 11,060 notional Ordinary Shares.
- Price per Share: £12.872.
- Total Gross Value: £142,364.32 (subject to tax withholding).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents the vesting of an award made on September 6, 2018, which occurred on February 15, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a specific transaction date (February 16, 2021) and does not address unusual items affecting the broader business.
Investor Verification Points
- Verify the tax withholding implications on the £142,364.32 gross payment to Mr. Simard.
- Confirm the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award programme referenced in the filing.
- Note that this filing does not replace or update the company's quarterly or annual financial statements.